Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in the following upcoming investor conferences.
| Event: | Canaccord Genuity Rare Disease, Biopharma One-on-One Day | |||||
| Date / Time: | Tuesday, February 3, 2015 | |||||
| Location: | Omni Berkshire Place Hotel, New York, N.Y. | |||||
| Event: | Leerink Global Healthcare Conference | |||||
| Date / Time: | Wednesday, February 11, 2015 at 1:50 PM (EST) | |||||
| Location: | Waldorf Astoria, New York, N.Y. | |||||
| Event: | SunTrust Robinson Humphrey Biotechnology and Pharmaceutical | |||||
One-on-One Orphan Drug Day | ||||||
| Date / Time: | Monday, February 23, 2015 | |||||
| Location: | JW Essex House, New York, N.Y. | |||||
| Event: | RBC Capital Markets’ Global Healthcare Conference | |||||
| Date / Time: | Tuesday, February 24, 2015 at 4:35 PM (EST) | |||||
| Location: | New York Palace Hotel, New York, N.Y. | |||||
Live audio webcasts for the Leerink and RBC Capital Markets events will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website (http://investor.acceleronpharma.com/events.cfm). A replay of the webcasts will also be available from Acceleron’s website.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com.
Contacts:
Kevin F. McLaughlin, 617-649-9204
Senior
Vice President and Chief Financial Officer
or
Media:
Suda
Communications LLC
Maureen L. Suda, 585-387-9248
